The Medical Use and Commercialization of
Human
Stem Cells
Part
1
March 2007
Covering
Adult Stem Cells From:
Bone marrow
Umbilical Cord
Peripheral Blood
Amnion and Placenta
This
report is offered as a single version.
Author's Note:
If you are non-technical reader, please do not be put off by the
scientific sections, they are vital to understand the field, its
potential and its issues. The scientific and medical content is
comprehensive but crafted to be
understood by a broad audience with a basic
familiarity of biology and
medicine.
Table of Contents
PREFACE
EXECUTIVE
SUMMARY
INTRODUCTION
- UNIT 1 -
Scientific
Background
Section 1. How the Cell Types Are Generated
The Primitive
Mesenchymal Cell
Bone marrow
Adipose Tissue
Cartilage
Bone
Muscle
Umbilical Cord and Placenta
Section 2.
Things You Should Know About the Implant Environment
Response to
Injury
Inflammatory Cells
Major Inflammatory Mediators
Major Angiogenic Factors
The Repair Factors
The Take Home Message
Section
3. The Major Targets for Adult Stem Cell Therapy (Mesodermal)
Hematopoietic
Reconstitution
Myocardial
Ischemia and Infarction
Bone Repair
Cartilage Repair
- UNIT 2 -
Reaching
the Marketplace
Section 1.
Common Factors Influencing Safety and Efficacy
(Note:
an introduction to these factors can be found in our White
Paper)
Robustness
Stability 
Functional Capacity
Influence of the Recipient
Supporting Factors Important for Success
Section 2.
Types of Business Models
The Service
Models
Tissue Banking
Tissue Processing
Cell Selection/Processing Reagents
The Biologic
(Biotech) Model
The Secondary Service Provider
Conclusion
Section 3. The
Non-Embryonic Mesodermal Stem Cell Populations --
Clinical, Product and Business Potential
Blood and Bone Marrow
Mesenchymal Cell Fractions From Bone Marrow and Adipose Tissue
Endothelial Cell Precursors From Bone Marrow, Blood and Adipose Tissue
Amniotic Epithelial Cells and Cells from Amniotic Fluid
Section 4. The
Primary Target Markets
Heart Disease
Cartilage and Bone Repair
-UNIT 3-
Company
Profiles
Introduction
Company Profile-
Focus
Location
Financing
Background/Technology
Business Model
Products/Potential Products
Pipeline Status
Competitive Strength
Competitive Threats - Current and Potential
Potential Competitors
What to Watch
Companies Profiled:
Aastrom
Biosciences Inc.
Aldagen
Amorcyte Inc.
Angioblast Systems Inc./Mesoblast Limited
Artecel Inc.
Athersys, Inc.
Cellerant Therapeutics, Inc.
Cytori Therapeutics
EndGenitor Technologies, Inc.
HealtheUniverse
MediStem
National Stem Cell Laboratory, Inc.
Neuronyx
Osiris Therapeutics
Saneron CCEL Therapeutics, Inc.
Stemnion LLC
Transtissue Technologies
TheraVitae
ViaCell
CONCLUSION
ILLUSTRATIONS
AND TABLES
Illustration 1.
Early Cell and Tissue Relationships
Illustration 2. A General Schema of Cell Lineage
Illustration 3.
The Role of Thrombospondin in Inflammation and Blood
Vessel Formation
Illustration 4.
The Cells, Factors and Phases of Angiogenesis
Illustration 5. Atherosclerotic Environment
Illustration 6. The Mesodermal Cell Lineages
Table 1. Company Overview by Source, Therapeutic Targets and Business
Model
Table 2. Venture Capital Firms That Have Invested in Adult Stem Cells
Table 3. Current Use of Cord Blood Transplants by Indication
Table 4. Companies Whose Businesses Will Rely on the Success of Adult
Stem Cells
BIBLIOGRAPHY
AND SUGGESTED READING
ADDITIONAL RESOURCES
Price:
$800.00 Digital, $825.00 Digital and Print
|
